Valneva SE (VALN) confirmed the previously announced timelines of its clinical trials and regulatory submissions for inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company continues to expect potential regulatory approvals in the first quarter of 2022. Also, Valneva expects to report topline data for the elderly trial in the coming weeks.
Valneva said it is preparing to launch a dedicated heterologous booster trial, which will evaluate a VLA2001 booster shot provided at least six months after primary vaccination with licensed COVID-19 vaccines or following natural COVID-19 infection.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.